Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Jiangsu Hengrui Medicine Co., Ltd.
  6. News
  7. Summary
    600276   CNE0000014W7

JIANGSU HENGRUI MEDICINE CO., LTD.

(600276)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Dalian Wanchun Brin Pharmaceutical Co., Ltd. announced that it expects to receive CNY 100 million in funding from Jiangsu Hengrui Medicine Co., Ltd.

08/25/2021 EST

Dalian Wanchun Brin Pharmaceutical Co., Ltd. announced that it has entered into a capital increase and shareholding agreement for a private placement of common shares for gross proceeds of CNY 100 million on August 25, 2021. The transaction will include participation from Jiangsu Hengrui Medicine Co., Ltd. As a result, the investor will own more than 2.5% stake in the company. The transaction does not need to be submitted to the investor's board of directors and shareholders' meeting for deliberation. The transaction still needs the approval of relevant government departments.


ę S&P Capital IQ 2021
All news about JIANGSU HENGRUI MEDICINE CO., LTD.
11/21CStone Pharma Grants Jiangsu Hengrui Rights to Investigational Cancer Drug in Greater C..
MT
10/19Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended S..
CI
08/26BeyondSpring Shares Up 17% After China Commercialization Deal
DJ
08/25Dalian Wanchun Brin Pharmaceutical Co., Ltd. announced that it expects to receive CNY 1..
CI
08/19Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended Jun..
CI
07/01MARKET CHATTER : China Adds New Drugs to Cover Under Health Insurance Program
MT
06/24China stocks slip as healthcare firms retreat; Hong Kong up
RE
05/21Jiangsu Hengrui Pharmaceuticals Co., Ltd. Announces on Obtaining Notice of Approval of ..
CI
05/03Shanghai Fosun Pharmaceutical's H-Shares Surge to All-Time High
DJ
04/19Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended..
CI
More news
Financials
Sales 2021 28 642 M 4 496 M 4 496 M
Net income 2021 6 377 M 1 001 M 1 001 M
Net cash 2021 18 500 M 2 904 M 2 904 M
P/E ratio 2021 50,2x
Yield 2021 0,35%
Capitalization 320 B 50 233 M 50 186 M
EV / Sales 2021 10,5x
EV / Sales 2022 8,99x
Nbr of Employees 28 903
Free-Float 46,7%
Chart JIANGSU HENGRUI MEDICINE CO., LTD.
Duration : Period :
Jiangsu Hengrui Medicine Co., Ltd. Technical Analysis Chart | 600276 | CNE0000014W7 | MarketScreener
Technical analysis trends JIANGSU HENGRUI MEDICINE CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 50,17 CNY
Average target price 68,91 CNY
Spread / Average Target 37,3%
EPS Revisions
Managers and Directors
Wei Dong Chairman-Supervisory Board
Piao Yang Sun Chairman
Shuang Xue Independent Director
Qian Wang Independent Director
Jia Hong Dong Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JIANGSU HENGRUI MEDICINE CO., LTD.-45.99%50 233
JOHNSON & JOHNSON-0.92%410 501
ROCHE HOLDING AG16.39%337 091
PFIZER, INC.45.97%301 579
NOVO NORDISK A/S65.17%243 741
ELI LILLY AND COMPANY46.91%224 871